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Abstract
Background: Heavy/light chain assay allows the characterization and quantification of immunoglobulin light chains
bound to heavy chains for each Ig’k and Ig’ immunoglobulin class, discriminating between the involved/uninvolved
isotypes in plasma cell dyscrasia. The Ig’k/Ig’ ratio (heavy/light chain ratio) enables to monitor the trend of monoclonal
component during therapy and disease evolution.
Objective: In this study, we evaluate the impact of the heavy/light chain assay in monitoring multiple myeloma patients in
comparison with conventional techniques.
Methods: Serum samples of 28 patients with IgG or IgA monoclonal component were collected for a mean of 109 days
and analyzed. The heavy/light chain assay was compared with classical immunoglobulin quantification (Ig’Tot), serum
immunofixation electrophoresis, serum protein electrophoresis, and serum-free light chains quantification. Serum sam-
ples from 30 healthy patients were used as control (polyclonal).
Results: Heavy/light chain ratio and serum immunofixation electrophoresis were comparable in 86% of the cases, and
free light chain ratio and heavy/light chain ratio in 71.8%. Heavy/light chain assay and Ig’Tot measurements showed a
concentration-dependent agreement in monoclonal patients. The heavy/light chain assay was able to quantify the mono-
clonal component migrating in SPE b region: this occurred in 10% of our IgG and 50% of our IgA patients.
Conclusions: The concordance scores indicate that heavy/light chain and Ig’Tot assays show differences at high mono-
clonal component values. The heavy/light chain ratio, serum immunofixation electrophoresis, and free light chain ratio
showed partial concordance. Our study confirmed that, in the context of heavy/light chain assay, heavy/light chain Ig’k and
Ig’ absolute values and heavy/light chain ratio are both important tools to monitor the presence of monoclonal com-
ponent that are difficult to be identified in SPE.
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Introduction
The monoclonal component (MC) quantification is
typically performed in plasma cell dyscrasia with
serum protein electrophoresis (SPE) followed by scan-
ning densitometry and nephelometry (Ig’Tot).1 Serum
immunofixation electrophoresis (S-IFE) and urine
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immunofixation electrophoresis (U-IFE) are used to
confirm the diagnosis and characterize the MC. These
approaches are simple and cheap,2 but present many
disadvantages: peaks densitometric measurement in
SPE is semi-quantitative and monoclonal spike (M-
spike) quantification can be inaccurate, depending on
the migration of the band.2,3 Nephelometric MC quan-
tification does not discriminate between MC and
normal polyclonal immunoglobulins, which become
particularly relevant at low MC concentrations.4 IFE
is a non-quantitative assay and requires expert inter-
pretation.5 Despite their limitations many physicians
use Ig’Tot quantification to monitor monoclonal pro-
teins, and some use both the M-spike and Ig’Tot quan-
tification to monitor treatment.6 In 2009 the Binding
Site developed a new immunoassay (the HevyliteTM
Assay, The Binding Site Ltd., Birmingham, United
Kingdom) to accurately quantify the involved and
uninvolved immunoglobulin isotype.3 This test uses
sheep polyclonal antibodies directed against the junc-
tional epitopes (constant region) between the heavy
chain and the light chain (heavy/light chain (HLC)):
thus HLC antibodies recognize the different immuno-
globulin class, i.e. IgGk, IgG, IgAk, IgA, IgMk, and
IgM. These molecules are then measured in pairs, e.g.
IgGk/IgG, to calculate the ratios of involved and
uninvolved immunoglobulins like the serum free light
chain (FLC) k/ ratios (3,7). Preliminary studies
employing the HLC assay have shown that HLC
ratios (HLCr) may be of use in screening, monitoring,
and risk stratifying of patients with multiple myeloma
(MM), Amyloid Light-chain (AL) amyloidosis,
Waldenström’s macroglobulinemia, and MGUS
(monoclonal gammopathy of undetermined signifi-
cance). In addition, they may provide the only sensitive
marker of disease progression in some patients.4
Here, we compared both HLCr and HLC absolute
values of monoclonal immunoglobulins with data
obtained performing S-IFE, free light chain ratio
(FLCr), and SPE densitometric quantification. In add-
ition, we evaluated the correlation and agreement of
Ig’Tot in comparison with Ig’kþ Ig’ HLC quantifica-
tion in both healthy donors (polyclonal) and patients
with plasma cell dyscrasia (monoclonal).
Material and methods
Clinical study and patients’ samples
During a one-year period, 28 patients (monoclonal)
presented to the Haematology ward and
Haematology day hospital of Azienda Ospedaliera
Spedali Civili of Brescia (AOSCB) for laboratory
screening or follow-up of monoclonal gammopathy
were included in the study. Samples included were
either from patients with suspect onset of MM (newly
diagnosed), plasma cell dyscrasia difficult to monitor,
and MM patients after autologous bone marrow trans-
plantation. Clinical diagnoses of patients were deter-
mined by local physicians. For each patient, serum
was collected sequentially after each control visit in
the Laboratory of Biochemical Chemistry after pro-
cessing for routine assays, according to International
Myeloma Working group7: SPE, S-IFE, nephelometric
measurement of immunoglobulin heavy chains
(Ig’Tot), and FLC quantification. On the day of the
withdrawal, an aliquot of the serum sample was
frozen at –80C for further analysis. Thirty blood
donors were used as healthy controls (polyclonal).
The institutional review board of AOSCB approved
the study in adherence with the Declaration of
Helsinki. All traceable identifiers were removed before
analysis to protect patient confidentiality, and all sam-
ples were analyzed anonymously.
Laboratory analysis
HLC assay
Immunoglobulin HLC pairs (IgGk/IgG, IgAk/IgA)
were measured using latex-enhanced immunoassay
(HevyliteTM, The Binding Site, Birmingham, UK)
on the turbidimetric platform Binding Site SPAPLUS
analyzer. Quantifications of these parameters were
used to determine the Ig’k/ig’ ratio (HLCr),
which was compared with reference ranges.8,9 The diag-
nostic ranges had been previously established by the
manufacturer: IgGk 3.84–12.07 g/L; IgG 1.91–6.74 g/
L; Gk/G 1.12–3.21; IgAk 0.57–2.08 g/L; IgA 0.44–
2.04 g/L; Ak/A 0.78–1.94. HLCr outside the reference
range was considered to be indicative of clonal
proliferation.3
SPE
Agarose gel electrophoresis and staining were per-
formed with the Microgel system on a G26 automated
instrument (Interlab, Rome, Italy). Gels were visually
interpreted for the presence of monoclonal gammopa-
thies and peaks densitometric scanning was performed
using the ‘‘Labware’’ software (Interlab).
S-IFE
S-IFE was performed with the Microgel system on a
G26 automated instrument (Interlab, Rome, Italy).
Heavy chains were stained using anti-IgG, -IgA, -IgM
antibodies. Light chain k or  antibodies were used.
Identification of the paraprotein isotype and light
chain was performed by visual interpretation.
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Quantification of immunoglobulins by nephelometry
(Ig’Tot)
IgA, IgG, IgM immunoglobulins (Ig’Tot) were mea-
sured by a nephelometric immunoassay (Dimension
Vista System Flex Reagent Cartridge) on a
Dimension Vista 500 (Siemens Healthcare Diagnostics
GmbH, Marburg, Germany). The diagnostic ranges
were established by the manufacturer: IgG 6.9–15 g/L,
IgA 0.85–4.1 g/L, IgM 0.4–2.4 g/L.
FLC assay
Serum FLC concentrations were measured using latex-
enhanced immunoassay (FreeliteTM, The Binding Site,
Birmingham, UK) on SPAPLUS analyzer. K FLC (ref-
erence range: 3.3–19.4mg/L),  FLC (reference range:
5.7–26.3mg/L), and k/ FLCr (reference range: 0.26–
1.65) ranges were previously established by the manu-
facturer. An abnormal FLC concentration was defined
as an increased k FLC and/or  FLC concentration
and/or abnormal ratio of k FLC to  FLC.1
Statistics
Patients (monoclonal) were divided into two groups
(IgA and IgG) according to MC isotype diagnosed
with S-IFE. Polyclonal IgA and IgG (polyclonal)
were quantified on healthy donor samples and analyzed
for each isotype separately. For correlation analysis,
Pearson’s correlation coefficient and linear regression
equation were calculated. The evaluation was per-
formed between Ig’Tot concentration of the involved
isotype and the sum of the HLC quantifications of
the involved and uninvolved isotype (Ig’kþ Ig’) in
both monoclonal and polyclonal groups. For agree-
ment analysis between the two methods, Bland–
Altman (BA) test and linear regression of difference
and average were determined. All statistics were per-
formed using GraphPad software (GraphPad
Software, Inc., La Jolla, CA, USA).
Results
Evaluation of concordance between S-IFE, FLC, and
HLC test
Sequential analysis on serum samples from 28 patients
admitted to the Haematology ward and sent to the
laboratory of Biochemical chemistry of AOSCB for
screening and follow-up of monoclonal gammopathy
was performed. Patients were followed for a mean of
109 days (range 26–204 days) between February 2013
and February 2014 and serum samples were collected
during each control visit. All patients were selected for
diagnosis (10/28 suspect onset of MM, 13/28 difficult to
monitor plasma cell dyscrasia, 5/28 MM patients after
autologous stem cell transplantation) and paraprotein
production. According to S-IFE, the majority of
patients included in the study presented a IgGk MC
(Figure 1(a)). SPE, Ig’Tot, FLC, and the HLC assay
were performed for all samples.
Qualitative S-IFE results were compared with
HLCr. Concordance, among the two tests, was set as
described: positive S-IFE and altered HLCr for the
same isotype or negative S-IFE and normal HLCr.
HLCr showed a concordance with S-IFE of 86% with
slight differences among each MC: 85% IgGk, 82%
IgG, 92% IgAk, 87% IgA.
FLCr was also compared with HLCr and 71.8% of
samples showed concordance between the two tests
(Figure 1(b)).
Ig’Tot and HLC assay correlation and agreement
We compared the Ig’Tot concentration with the
summed concentration of the Ig’kþ Ig’ HLC assay
from 30 healthy donors serum samples (polyclonal)
both for IgG and IgA isotype. We assumed that the
Ig’Tot concentration of the involved isotype and the
sum of the HLC quantifications of the involved and
uninvolved isotype (Ig’kþ Ig’ concentration) could
be the same. As shown in Figure 2(a) and (b) in poly-
clonal patients, IgATot and IgAkþ IgA HLC
showed a good correlation (Pearson correlation coef-
ficient r: 0.93, 95% confidence interval (CI) 0.86–0.96)
and agreement (BA bias: 7.8 [absolute value], 95%
limits of agreement [LA]: from –49.93 to 65.86, differ-
ence versus average linear regression X¼0.071
[slope of the line], not significantly different from
0),10 in IgG polyclonal (Figure 2(c) and (d)) the two
tests show a quite good correlation (r: 0.86, 95% CI
0.73–0.93) and agreement (BA bias –190.8, BA 95%
LA: from 495.7 to 114.2 difference versus average
linear regression X¼0.054, not significantly different
from 0) between the two methods. We applied the
same statistical analyses at IgA or IgG MC and we
noticed that in IgA monoclonal patients the two meth-
ods still correlate (r: 0.96, 95% CI 0.92–0.99) while
this correlation is weaker in IgG (r: 0.79, 95% CI
0.67–0.87) (Figure 3(a) and (b)). BA analysis for
both IgA and IgG shows that there is a concentra-
tion-dependent discordance, especially in IgG MC
patients (Figure 3(c) and (d)): at high MC concentra-
tion agreement among the two test is completely lost.
The LA of BA tests are wider in monoclonal patients
than in polyclonal even after log transformation of the
original data (data not shown).11 At high MC concen-
trations there is also an opposite trend in IgA and IgG
patients. IgATot values are lower than IgAkþ IgA
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HLC quantification (difference versus average linear
regression x¼0.36, significantly different from 0: p
value <0.001; BA bias –122) while, in IgG patients,
IgGTot values are higher than IgGkþ IgG HLC
quantifications (difference versus average linear regres-
sion x¼ 0.2, significantly different from 0: p
value¼ 0.018, BA bias 459.2).
Comparison between SPE and HLC
In this study we evaluated the MC quantification of the
g peak with the HLC measurement of the involved
isotype and HLCr for every patient (supplementary
data, Figures 1 to 4). In 76% of patients, HLC quan-
tification of the involved isotype shows a similar trend
with MC quantification during the monitoring time as
shown in Figure 4(a), Patient 3.
In this study we confirmed that HLC quantification
is an important tool and HLCr is a very helpful par-
ameter to monitor MC, which cannot be quantified by
densitogram scan. Indeed this problem occurred in 11/
28 patients: for six patients (patient 2, 4, 5, 13, 34, 39,
supplementary data, Figures 1 to 3) MC quantification
was not possible at one or more time points while in five
patients (patient 1, 11, 15, 28, 31, supplementary data,
Figure 4) the MC migrates in the b region of SPE
Figure 1. FLC ratio versus HLC ratio concordance. (a) Monoclonal component distribution, according to S-IFE, of patients included
in the study. (b) Concordance analysis for the FLC Ratio (FLCr) and HLC Ratio (HLCr). Concordance was set as described: both
altered or normal FLCr and HLCr (gray areas). Discordant results were set if one ratio was altered and the other one was normal
(white area). Percentage and number of measurements (in brackets) are also shown.
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densitogram. Among the last group, 80% were IgA
patients and 20% IgG patients, confirming that mono-
clonal IgA immunoglobulins frequently migrate in b
region.4,12,13 In contrast, HLC quantification was
obtained for all patients and HLCr calculated.
Figure 4(b) shows the follow-up of patient 11 after
autologous bone marrow transplantation. In 2011 the
patient was admitted to the hospital and diagnosed as a
IIIA IgAK MM. After four cycles of chemotherapy
and autologous bone marrow transplantation, MM
completely remitted and patient underwent the
follow-up. After two years the patient presented lower
back pain (T0). S-IFE showed the presence of an IgAk
MC not quantifiable due to its migration in b region at
SPE densitogram. IgATot was out of the reference
ranges (27.1 g/L), but k FLC value was normal (k
14.5mg/L). The  FLC concentration was under the
test’s detection limits (< 0.01mg/L) so the k/ FLC
ratio was not computable (NQ). The IgAk/IgA ratio
was strongly altered (IgAk/IgA 184.88, IgAk 35.13 g/
L, IgA 0.19 g/L) while the IgGk/IgG ratio was
normal (IgGk/IgG 2.32, IgGk 2.94, IgG 1.26) con-
firming the presence of an IgAk MC. The patient
started a new cycle of treatment and after 14 days
(T14) the clinical picture was unchanged with elevated
IgATot (27.52 g/L), k/ FLC ratio NQ, altered IgAk/
IgA ratio, and MC migrating in b in SPE. As T34
IgATot decreased (5.11 g/L), k/ FLC ratio normalized
and only IgAk/IgA ratio remained altered (IgAk/IgA
48.89, IgAk 9.04 g/L, IgA 0.185 g/L). After the third
(T55) and fourth cycle (T96) of therapy, according to
IgATot and k/ FLC ratio, the clone seemed to
Figure 2. Correlation and agreement of polyclonal IgG and IgA samples. Plots represent linear regression analysis of Ig’Tot con-
centration with summed concentration of the Ig’kþ Ig’ HLC assay from polyclonal serum samples both for IgA (a) and IgG (c)
isotype. Linear regression equation, R square, and Pearson correlation factor r were also calculated and represented. Bland–Altman
test plots of Ig’Tot concentration with summed concentration of the Ig’kþ Ig’ HLC for polyclonal IgA (b) and polyclonal IgG (d).
Linear regression equation and the bias of the average of the differences were calculated for every graph.
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respond to treatments and only the IgAk/IgA ratio
highlighted the suspect of therapy resistance (IgAk/
IgA ratio 2.38 (T55), 2.04 (T96)). At T134 this suspect
was confirmed because all monitored parameters
increased (IgATot 5 g/L, k/ FLC ratio 2.31, IgAk/
IgA 24.49) and S-IFE became positive again, indicat-
ing an evolving relapse.
Discussion
HLC assay quantifies immunoglobulins using poly-
clonal antibodies targeted at unique junctional epitopes
between heavy-chain and light-chain constant region of
intact Ig. This allows to distinguish between the Ig’k
and Ig’ and to calculate the ratio of the two isotypes,
identifying the involved and uninvolved isotype in a
monoclonal gammopathy. Since 2009 this test has
been proposed to support routine lab assays (SPE,
S-IFE, FLC assay, nephelometric measurement of
immunoglobulin heavy chains of serum), and in some
cases to overcome their limits in the management of
patients with monoclonal gammopathy.14 In our
study we compared the qualitative assay S-IFE with
the quantitative data obtained from HLCr: in most
cases results are comparable, especially for the IgAk
MC. Among discordant patients, in 73% of cases
HLCr were within normal limits, but S-IFEs were posi-
tive even if the MC trend decreased (with HLC meas-
urements and SPE quantification). Our results confirm
the utility of the HLC assay to identify and quantify the
MC, even when SPE and S-IFE are difficult to be
evaluated.
Figure 3. Correlation and agreement of monoclonal IgG and IgA samples. Plots represent linear regression analysis of Ig’Tot
concentration with summed concentration of the Ig’kþ Ig’ HLC assay from monoclonal serum samples both for IgA (a) and IgG (c)
isotype. Linear regression equation, R square, and Pearson correlation factor r were also calculated and represented. Bland–Altman
test plots of Ig’Tot concentration with summed concentration of the Ig’kþ Ig’ HLC for monoclonal IgA (b) and polyclonal IgG (d).
Linear regression equation and the bias of the average of the differences were calculated for every graph.
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Figure 4. Monoclonal samples characterization. (a) The graphs show trend of HLC quantification of the involved isotype, HLC ratio
(red line, triangles), and band densitometric quantification of SPE (green line) in sequential serum measurements for patient 3. Table
shows patient characteristics for all the data points analyzed. Patient 3 SPE densitogram and serum immunofixation electrophoresis (S-
IFE) highlighting an IgG MC migrating in g region of SPE. (b) The graphs show trend of HLC quantification of the involved isotype,
HLC ratio (red line, triangles), and band densitometric quantification of SPE (green line) in sequential serum measurements for patient
11. Table shows patients characteristics for all the data points analyzed. Patient 11 SPE densitogram and S-IFE highlighting an IgAK MC
migrating in b region of SPE.
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According to the International Myeloma Working
Group (IMWG) guidelines,7 in addition to S-IFE and
SPE, serum FLC should be measured at diagnosis for
all patients with MGUS, smoldering or active MM,
solitary plasmacytoma, and AL amyloidosis. FLC
assay is routinely used to monitor disease activity and
relapse after therapy or autologous transplant even if
85% of MM secrete a whole paraprotein, 13% secrete
only FLC, and 2% are oligo/non-secretory MM.15 All
our patients were selected for whole immunoglobulin
production and FLCr failed to detect MC alteration in
25% of the cases. In this scenario, HLC assay can be a
valuable support to FLC assay to monitor MM evolu-
tion, especially in those patients with an intact immuno-
globulin MC.16
Nephelometric measurement of immunoglobulin
heavy chains of serum (Ig’Tot) is in the repertoire of
tests to document and measure the immunoglobulins.1
In normal practice nephelometric measurement of
immunoglobulin heavy chains of serum (IgG, IgA,
IgM) is used to monitor the MC behavior even if there
are some limits: when the paraprotein production
increases the involved isotype should increase, while usu-
ally there is a consequential immunoglobulin suppression
of the uninvolved isotype.16 Despite the quantitative
results, this test cannot distinguish between the
involved/uninvolved isotype as HLC assay and this can
lead to aspecific antibody reactivity that alter the MC
quantification. When the immunoglobulins are in the ref-
erence ranges, as seen in polyclonal patients, the two tests
(Ig’Tot and Ig’kþ Ig’ HLC) show a certain correlation
(IgA polyclonal linear regression equation y¼ 0.9972X–
7.398; IgG polyclonal y¼ 0.9069þ 297.1), but they are
not perfectly in agreement. Our results appeared less sat-
isfactory than the data obtained by Bradwell et al.,14 how-
ever this could be due to the limited number of our data-
set. Instead, in the presence of a high MC concentration
(monoclonal patients) the agreement is completely lost
and quantifications obtained with the two assays are
more discordant. Our results highlight that, similar to
FLC measurements, for patients producing paraproteins
the antiserum could display different antigen–antibody
interactions generating macromolecular immunocom-
plexes giving rise to different light absorption/diffraction
properties affecting the analytical measurements.17 These
data confirm the differences between the two methods
and the lack of accuracy monitoring MC only with the
Ig’Tot measurement.14
According to the IMWG, one of the gold standard
tests for MM screening is SPE.7 This technique allows a
semi-quantitative measurement of the MC with a densi-
tometric scan of g peak in the electrophoretic pattern.
In our study we confirmed that HLC assay is a useful
tool to monitor MC migrating in b region of the SPE,
where it is obscured by proteins such as transferrin, b
lipoprotein, and C3, which preclude quantification.4
We monitored 28 patients for MM screening and
follow-up for a median of 95 days and HLC assay
was always able to quantify the MC component, even
if not quantifiable in SPE. This problem is quite
common since SPE has a limit of quantification of
0.5–2 g/L depending on the migration characteristics
of MC-Ig bands14 and can be due to patient immuno-
suppression. Furthermore, we confirmed that HLC
quantification could be a sensitive assay to detect
early relapse especially in patients presenting not quan-
tifiable MC (patients 11, Figure 4(b) and patient 15,
supplementary Figure 5).4 In the small group of
patients with MC migrating in b region, we compared
HLCr with FLCr. In 2/5 patients (patient 11 and 15,
Figure 4 and supplementary Figure 5) the ratios were
different in one or more data points. In 3/5 patients
HLCr and FLCr were comparable (patient 1, 28, 31,
supplementary Figure 4). These differences highlight
the importance of considering every single patient as
a unique case. In conclusion, the findings presented
indicate that HLC assay can support traditional meth-
ods to characterize MC at disease onset and monitor
monoclonal gammopathies along therapy and
follow-up processes. Similar to FLC assay, HLC
can be a robust alternative to invasive procedure,
such as osteo-medullary biopsy, to monitor MM
progression.
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